Ipsat Therapies Oy Company Profile

20:45 EDT 21st March 2018 | BioPortfolio

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance


Helsinki Business and Science Park
Viikinkaari 4


Phone: 358 9 3193 6500
Fax: 358 9 3193 6519

News Articles [199 Associated News Articles listed on BioPortfolio]

Patient adherence to oral therapies

Dr Ginah Nightingale talks to ecancer at SIOG 2017 in Warsaw. She discusses the adherence of oral therapies by patients. Dr Nightingale suggests that by observing their commitment to other therapies...

FDA Sets Path for Stem Cell Therapies

(CNN) – Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the develop...

Opinion: Revolutionary new cancer therapies come with big risks. Drug makers must be prepared

CAR-T therapies will almost certainly kill some patients faster than their underlying cancers would have. Companies and clinicians must prepare for that.

Evotec, CRTD partner to discover novel therapies for retinal diseases

Evotec has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden (CRTD) to discover novel small molecule candidates for retinal diseases. CRTD is a recognized lea...

Product characterisation key to successful CAR T therapies, Autolus

CAR T-cell understanding must come before the process design if such therapies are ever going to be accessible to a larger patient population, says Autolus.

STAT Plus: Read the live chat transcript: Cancer therapies take center stage at ASH

Cancer killing CAR-T therapies will once again dominate this year’s ASH meeting, but with an important difference: They're now on the market.

Seven therapies backed for EU approval

Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.

Regulatory approvals and innovation drives: Cell therapies come of age

Cell therapies have reached their 'teenage years' and must now overcome processing efficiencies and quality struggles, say industry delegates.

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Hepsera [Excella GmbH]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Hepsera [Gilead Sciences, Inc.]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Olay total effects uv moisturizer [Procter & Gamble Manufacturing Company]

OLAY total effects

PubMed Articles [551 Associated PubMed Articles listed on BioPortfolio]

Mind-Body Therapies in Cancer: What Is the Latest Evidence?

Many people living with cancer use complementary therapies, and some of the most popular are mind-body therapies (MBTs), including relaxation and imagery, hypnosis, yoga, meditation, tai chi and qigon...

Efficacy of Pain Relief in Different Postherpetic Neuralgia Therapies: A Network Meta-Analysis.

Postherpetic neuralgia (PHN) is a nerve pain disease usually controlled by different therapies, i.e., topical therapies, antiepileptics, analgesics, antipsychotics, antidepressants, anti-dementia drug...

A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.

Systemic immunomodulatory therapies are the principal means of managing non-infectious uveitis. This review aims to explore the current landscape of systemic uveitis treatments, including biologic the...

Funding breakthrough therapies: A systematic review and recommendation.

Advanced therapy medicinal products (ATMPs) are innovative therapies likely associated with high prices. Payers need guidance to create a balance between ensuring patient access to breakthrough therap...

Palliative Therapies for Congenital Heart Disease with Ductus Dependent Pulmonary Circulation.

In neonates, the management of ductus dependent pulmonary circulation is challenging. There have been three palliative therapies for this lesion: the modified Blalock-Taussig shunt, ductal stenting an...

Clinical Trials [1440 Associated Clinical Trials listed on BioPortfolio]

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

The proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (CAM) therapies to understand the selection of patients and CAM ther...

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for wh...

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment wi...

Intensive Therapies in Children With Hemiplegia

This is a comparative study where two protocols of intensive therapies will be applied to study the improvements in the functional performance of the affected upper limb of children with h...

Dysphagia After Different Swallowing Therapies

Dysphagia after stroke is associated to increased pulmonary complications and mortality. The swallowing therapies could decrease the pulmonary complications and improve the quality of life...

Companies [818 Associated Companies listed on BioPortfolio]

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospita...

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

MolMed S.p.A.

Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is an integrated company covering all functions, from di...

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ( develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including: ...

WuXi AppTec

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along wi...

More Information about "Ipsat Therapies Oy" on BioPortfolio

We have published hundreds of Ipsat Therapies Oy news stories on BioPortfolio along with dozens of Ipsat Therapies Oy Clinical Trials and PubMed Articles about Ipsat Therapies Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsat Therapies Oy Companies in our database. You can also find out about relevant Ipsat Therapies Oy Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...

Corporate Database Quicklinks

Searches Linking to this Company Record